3 ASX shares poised to rise 50% by 2025

In a volatile market, these names could outshine next year.

| More on:
A person sitting at a desk smiling and looking at a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Prudent investors in ASX shares will no doubt be breathing easier on Wednesday following the recent market volatility. However, visibility on what's next is not clear.

It was Roman author Pliny the Elder who wrote "In wine, there is truth".

But markets reveal their own truth, eternalised by none other than the great Warren Buffett's saying: "When the tide goes out, we see who's been swimming naked".

As many of the retail investor lambs were fleeced this past week, big institutional wolves subsequently came in and gobbled up the leftovers, according to Goldman Sachs.

This tells me to remain constructive on ASX shares for the long term, as 'smart money' is putting its money where its mouth is – even if that mouth is very shark-like.

So, if you're looking for ASX stocks that analysts believe could see substantial gains in the future, stick around. Here are three.

ASX shares to lift

There are actually a few candidates to mention here, but I've narrowed it down to three with strong broker support.

Mineral Resources Ltd (ASX: MIN) is the first name. It's currently trading at $52.30 per share, down 10% in the past month.

Analysts at Bell Potter are optimistic about the lithium miner, forecasting significant production growth that could drive earnings higher.

This increased capacity could see the ASX share benefiting from lower unit costs and tighter commodity prices.

The broker rates Mineral Resources a buy with a price target of $80 per share, implying a 52% upside from current levels.

Fund managers L1 Capital also like the stock. According to my colleague Tristan, it noted that its business divisions all "have favourable medium-term tailwinds", and that it "remains significantly undervalued".

Liontown Resources Ltd (ASX: LTR)

Liontown Resources has had a tough year, but it could be worth considering, particularly for those with a higher risk budget.

The ASX share is trading at 90.5 cents per share at the time of writing, down more than 67% in the last year.

Bell Potter maintains a speculative buy rating on Liontown. According to my colleague James, in a July note, the broker doubled its price target to $1.90 per share.

This suggests a potential upside of 110% over the next year.

Bell Potter says Liontown's Kathleen Valley Lithium Project is progressing well, with spodumene concentrate production set to commence soon. The project is nearly complete, with underground and open-pit mining advancing as planned.

Goldman Sachs also projects revenues to grow at a 74% compounding rate from $143 million in FY25 up to $1.32 billion by FY29.

It values the ASX share at $1.15 apiece, not quite a 50% return, but around 27% upside potential instead.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Neuren Pharmaceuticals is also making waves in the healthcare sector with its innovative treatments for neurodevelopmental disorders.

The ASX share was put on ice today pending an announcement for its NZ-2591 compound, indicated in the treatment of various neurodevelopment disorders.

Neuren also posted its Q2 results on Wednesday, along with the second quarter results of its partner, Acadia Pharmaceuticals Inc (NASDAQ: ACAD).

The major takeout from the quarter was the royalties it booked on Acadia's sales of its Rett syndrome treatment, Daybue.

Acadia's Daybue sales were US$84.6 million during the quarter, earning Neuren AUD$13 million in royalty income from this.

Bell Potter is bullish on the ASX share. It projects that Neuren shares could reach $28.00 apiece, a 63% increase from current levels.

Takeout

According to top brokers, Mineral Resources, Liontown Resources, and Neuren Pharmaceuticals are three ASX shares with substantial growth potential.

Each company has individual drivers. But as always, ensure you conduct your own due diligence and consider your investment goals before making any decisions.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Human head and artificial intelligence head side by side.
AI Stocks

The future of AI: Best ASX shares to buy now

Brokers are backing these 3 ASX shares for future growth amid the artificial intelligence revolution.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Broker Notes

These ASX shares could rise 19% and 35%

Analysts expect these shares to deliver big returns over the next 12 months.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Broker Notes

2 exciting ASX shares this fund manager thinks are buys

These stocks could be exciting opportunities to buy.

Read more »

Three happy construction workers on an infrastructure site have a chat.
Resources Shares

3 ASX lithium stocks primed for an electric performance: Macquarie

Time to charge up?

Read more »

Three happy multi-ethnic business colleagues discuss investment or finance possibilities in an office.
Broker Notes

ASX financial shares are up 33% this year. Brokers reveal which stocks to buy for 2025

After such a stellar run, are there any good buys left among ASX financial shares?

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Broker Notes

3 reasons to buy this ASX 200 stock now

Bell Potter thinks investors should be snapping up this stock right now.

Read more »